Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

Phase 3

Completed

Conditions: Gastric Adenocarcinoma

Interventions: Biological: Pembrolizumab
Drug: Cisplatin
Drug: 5-FU
Drug: Placebo
Drug: Capecitabine

First Posted Date: 2015-07-10

Last Posted Date: 2023-04-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 763

Registration Number: NCT02494583

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Neuroendocrine Tumors
Small Cell Carcinoma
Ovarian Epithelial Cancer

Interventions: Drug: Cisplatin
Drug: RRx-001
Drug: Carboplatin
Drug: Etoposide
Drug: Paclitaxel
Drug: Doxil
Drug: Irinotecan
Drug: Nab-Paclitaxel
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Taxane
Drug: Pemetrexed

First Posted Date: 2015-07-03

Last Posted Date: 2022-10-03

Lead Sponsor: EpicentRx, Inc.

Target Recruit Count: 139

Registration Number: NCT02489903

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Baptist Health, Lexington, Kentucky, United States
🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States

and more 7 locations

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab
Drug: Cisplatin
Drug: Vinorelbine
Drug: Docetaxel
Drug: Gemcitabine
Drug: Pemetrexed

First Posted Date: 2015-07-01

Last Posted Date: 2024-08-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1280

Registration Number: NCT02486718

Locations: 🇪🇸
Hospital NisA 9 de Octubre, Valencia, Spain
🇨🇳
Zhejiang Cancer Hospital, Zhejiang, China
🇫🇷
Hôpital Universitaire Dupuytren, Limoges, France

and more 225 locations

Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy

Phase 4

Completed

Conditions: Patients With Head and Neck Cancer (ORL)

Interventions: Drug: Cisplatin
Drug: Docetaxel
Drug: 5-Fluorouracile

First Posted Date: 2015-06-30

Last Posted Date: 2023-05-26

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Target Recruit Count: 12

Registration Number: NCT02484677

Locations: 🇫🇷
Assistance Publique Hôpitaux de Marseille, Marseille, France

Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer

Phase 3

Conditions: Head and Neck Squamous Cell Cancer

Interventions: Drug: Raltitrexed
Drug: 5-fluorouracil
Drug: Cisplatin
Radiation: IMRT

First Posted Date: 2015-06-30

Last Posted Date: 2015-06-30

Lead Sponsor: Jiangsu Cancer Institute & Hospital

Target Recruit Count: 120

Registration Number: NCT02485548

Locations: 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Nivolumab
Drug: Carboplatin
Drug: Ipilimumab
Drug: Gemcitabine
Drug: Cisplatin
Drug: Pemetrexed
Drug: Paclitaxel

First Posted Date: 2015-06-23

Last Posted Date: 2024-11-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 2748

Registration Number: NCT02477826

Locations: 🇺🇸
Local Institution - 0017, San Francisco, California, United States
🇺🇸
Local Institution - 0115, Saint Louis, Missouri, United States
🇺🇸
Local Institution - 0014, Cleveland, Ohio, United States

and more 287 locations

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

Phase 1

Active, not recruiting

Conditions: Head and Neck Cancer Metastatic
Recurrent Head and Neck Carcinoma
Head or Neck Cancer

Interventions: Radiation: Intensity Modulated Radiation Therapy (IMRT)
Drug: Cisplatin
Radiation: Stereotactic Body Radiotherapy (SBRT)

First Posted Date: 2015-06-17

Last Posted Date: 2024-07-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT02474368

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

Phase 3

Active, not recruiting

Conditions: Advanced Vaginal Adenocarcinoma
Stage II Cervical Cancer AJCC v7
Stage IIB Cervical Cancer AJCC v6 and v7
Stage IVA Vaginal Cancer AJCC v6 and v7
Unresectable Vaginal Carcinoma
Vaginal Adenocarcinoma
Cervical Adenocarcinoma
Stage IIIB Cervical Cancer AJCC v6 and v7
Stage IVA Cervical Cancer AJCC v6 and v7
Cervical Adenosquamous Carcinoma

Interventions: Radiation: Brachytherapy
Drug: Cisplatin
Radiation: External Beam Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Radiation: Radiation Therapy
Drug: Triapine

First Posted Date: 2015-06-09

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 450

Registration Number: NCT02466971

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
Memorial Hermann Texas Medical Center, Houston, Texas, United States
🇺🇸
Methodist Willowbrook Hospital, Houston, Texas, United States

and more 380 locations

Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)

Phase 3

Active, not recruiting

Conditions: Esophageal Cancer
Oesophageal Cancer
Esophageal Squamous Cell Carcinoma

Interventions: Drug: Docetaxel
Drug: Cisplatin
Radiation: Radiation
Drug: Vinorelbine
Procedure: Surgery

First Posted Date: 2015-06-08

Last Posted Date: 2024-01-16

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 610

Registration Number: NCT02465736

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

Phase 3

Active, not recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Gemcitabine
Drug: cisplatin
Radiation: Intensity-modulated Radiotherapy

First Posted Date: 2015-06-03

Last Posted Date: 2024-12-03

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 236

Registration Number: NCT02460887

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy